艾迪注射液联合化疗治疗晚期上皮性卵巢癌的疗效观察  

Efficacy of Aidi Injection combined with chemotherapy in the treatment of advanced epithelial ovarian cancer

作　　者：叶聪[1] 黄琼卫 胡宇博[1] YE Cong;HUANG Qiongwei;HU Yubo(Department of Obstetrics and Gynecololgy,China-Japan union hospital of Jilin University,Changchun 130033,China)

机构地区：[1]吉林大学中日联谊医院妇产科,长春130033

出　　处：《长春中医药大学学报》2020年第6期1246-1248,共3页Journal of Changchun University of Chinese Medicine

基　　金：干细胞在子宫黏连中子宫内膜修复的机制研究(3R218I293430)。

摘　　要：目的探究艾迪注射液联合常规化疗对晚期上皮性卵巢癌患者的疗效及生存质量的影响。方法选取晚期上皮性卵巢癌患者68例,随机分为观察组和对照组,各34例。对照组接受常规化疗治疗,观察组联合艾迪注射液进行治疗。观察对比2组的临床疗效、生活质量差异和不良反应发生情况等。结果观察组的临床有效率(88.2%,30/34)高于对照组(61.8%,21/34)(P<0.05)。观察组的生活质量改善明显优于对照组,差异有统计学意义(P<0.05)。观察组的不良反应(白细胞下降、恶心呕吐)发生率明显低于对照组(P<0.05)。结论艾迪注射液联合常规化疗可提高晚期上皮性卵巢癌的治疗效果,与单独化疗相比,可以降低不良反应发生,提高患者生活质量。Objective To study the efficacy,quality of life and side effects of Aidi Injection combined with paclitaxel and cisplatin in the treatment of advanced epithelial ovarian cancer.Methods A total of 68 cases of advanced epithelial ovarian cancer were randomly divided into 2 groups,observation group and the control group,34 cases in each group.The patients in the control group were treated with chemotherapy,and the patients in the observation group were treated with Aidi Injection combined with chemotherapy.Results The effective rate of the patients in the observation group had no different with that of the control group(88.2%to 61.8%)(P<0.05),the improvement of quality of life in the observation group was better than that of the control group,and the difference was statistically significant(P<0.05),the incidence of leukocyte decline,abdominal pain and nausea in the observation group were significantly lower than those in the control group(P<0.05),and the difference was statistically significant.Conclusion Aidi Injection combined with paclitaxel and cisplatin is safe and effective in the treatment of advanced epithelial ovarian cancer.Compared with chemotherapy alone,it improves the life and does not increase toxicity.

关 键 词：晚期上皮性卵巢癌 艾迪注射液 紫杉醇 顺铂 

分 类 号：R737.31[医药卫生—肿瘤]